New formulation helps RNA vaccines withstand high temperatures (news.mit.edu)

Researchers at MIT have developed a new formulation for RNA vaccines that enhances their heat resistance, addressing a significant limitation in their storage and distribution requirements. Utilizing an AI algorithm, the team optimized the lipid nanoparticle (LNP) formulations traditionally used to protect RNA, enabling vaccines to remain stable for up to a year at room temperature and for two months at nearly 100 degrees Fahrenheit. This advancement not only promises to extend the reach of RNA vaccines beyond COVID-19 to other diseases, such as cancer but also facilitates novel delivery methods like microneedle patches. The AI-driven approach allowed researchers to streamline the experimental process, rapidly discovering optimal formulations using small datasets. They analyzed nearly 50 FDA-approved excipients to identify effective combinations for enhancing stability. Their successful tests demonstrated that vaccinated mice exhibited strong immune responses comparable to those receiving conventional mRNA vaccines. This work may revolutionize vaccine storage logistics, making it feasible to distribute RNA vaccines in areas lacking cold storage while potentially improving the efficacy and delivery methods of a range of therapeutic applications.